the Effect Between Platelet Reactivation and Antiplatelet Drugs
This trial is active, not recruiting.
|Conditions||drug effect disorder, platelet procoagulant activity deficiency|
|Sponsor||Beijing Anzhen Hospital|
|Start date||May 2014|
|End date||December 2015|
|Trial size||74 participants|
|Trial identifier||NCT02198053, azliquan|
Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes. Compared with clopidogrel, Ticagrelor is more powerful antiplatelet drug. However, because of increased bleeding and dyspnea risk, both loading double dose and following second dose time had potential risk and inconvenient in routine clinical work, especially in elective PCI of comparable stable patients in Chinese. The benefit and risk should be balanced in such patients. The investigators supposed loading single dose and followed by second routine time dose was superior to clopidogrel and safer than ticagrelor previously prescribed.
|Observational model||case control|
Ticagrelor with a loading dose of 180mg followed by 90 mg twice per day
Ticagrelor with a dose of 90mg followed by 90 mg twice per day .
time frame: 1 year
Male or female participants of any age.
Inclusion Criteria: coronary artery disease, percutaneous coronary intervention Exclusion Criteria: high risk bleeding patient, allergic to the drugs
|Official title||Effect of 180 mgTicagrelor Compared With 90 mg Ticagrelor on Platelet Reactivity in Patients Undergoing Elective PCI.|
|Description||All admission patients were divided into two groups, the first group were prescribed loading dose (180 mg) ticagrelor, the second group were prescribed with 90 mg ticagrelor. We measured both platelet activity and platelet reactivity using the LTA at baseline, pre-operation and post-operation. All bleeding or dyspnea events were recorded in hospital period. Primary endpoints: platelet activity, platelet reactivity using the LTA and safety events were recorded in hospital period.|
Call for more information